PREVENTION OF SIMIAN AIDS BY AN INACTIVATED TYPE-D VIRUS VACCINE

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

PREVENTION OF SIMIAN AIDS BY AN INACTIVATED TYPE-D VIRUS VACCINE

Vaccines 87. Modern Approaches to New Vaccines: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Chanock RM et al, eds. New York, Cold Spring Harbor Laboratory, p. 260-2, 1987.. Unique Identifier : AIDSLINE ICDB/88647988
Gardner M; Marx P; Lerche N; Maul D; Sutjipto S; Kwang HS; Pederson N; Dept. of Medical Pathology, California Regional Primate Center,; Univ. of California, Davis, CA 95616

Abstract: Simian acquired immunodeficiency syndrome (SAIDS) is a spontaneous, often fatal disease that occurs in eight species of Asian macaques at four primate research centers in the United States. Because of the practical importance of this disease and because fatal SAIDS could be repeatedly induced in juvenile rhesus monkeys by natural cage exposure, by iv inoculation of tissue culture-purified type-D virus (SRV-1 strain), and, more recently, by molecularly cloned SRV-1, the effect was tested of a formalin-inactivated whole SRV-1 vaccine against the experimental induction of SAIDS with this virulent virus. Six monkeys were vaccinated. All six immunized juvenile rhesus monkeys developed a high titer of neutralization antibodies (titer 1:40-1:320) after immunization and were completely protected against persistent viremia and disease 1 yr post-challenge. Western blot analysis confirmed that the antibodies in the vaccinated monkeys reacted with SRV-1 envelope antigens (gp70) and core (p27) antigens. In contrast, four of six controls, given adjuvant only, developed persistent viremia and clinical SAIDS within a few weeks post-challenge, and three animals died of SAIDS at 2.5, 8, and 11 mo post-challenge. The vaccine or adjuvant alone was nontoxic, did not produce swelling or fever, and only transient regional lymphadenopathy occurred in both groups. The results show complete protection of susceptible juvenile macaques against the experimental induction of SAIDS by inoculation of SRV-1. (9 Refs)

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/PREVENTION & CONTROL/*VETERINARY Animal Antibodies, Viral/ANALYSIS HIV/*IMMUNOLOGY Macaca mulatta/MICROBIOLOGY Monkey Diseases/*PREVENTION & CONTROL Retroviridae/*IMMUNOLOGY Vaccination Vaccines, Attenuated/*ADMINISTRATION & DOSAGE Viral Envelope Proteins/IMMUNOLOGY Viral Vaccines/*ADMINISTRATION & DOSAGE MEETING PAPER

881130
M88B0607

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .